Quest Diagnostics Inc announces European availability of the Simplexa Flu A/B & RSV Direct test, which recently earned the CE mark, on the 3M™ Integrated Cycler. The new test, from the company’s Focus Diagnostics business, uses a proprietary technique to eliminate nucleic-acid sample extraction.
Nucleic-acid extraction is a process requiring specialized molecular equipment and trained personnel. It involves extracting DNA or RNA from a blood, plasma, or other specimen type for testing. The nucleic-acid extraction process used in most commercial molecular test kits can add approximately 60 to 90 minutes to total testing time. Focus Diagnostics has replaced the process with a proprietary reaction-mix technique. The company expects to use the proprietary technology in future Simplexa products.
Source: Quest Diagnostics Inc
